|5.||Acute Coronary Syndrome
|1.||Stone, Gregg W: 340 articles (01/2016 - 01/2002)|
|2.||Mehran, Roxana: 222 articles (01/2016 - 01/2002)|
|3.||Gibson, C Michael: 176 articles (10/2015 - 01/2002)|
|4.||Braunwald, Eugene: 171 articles (11/2015 - 02/2002)|
|5.||Serruys, Patrick W: 170 articles (12/2015 - 02/2002)|
|6.||Cannon, Christopher P: 157 articles (10/2015 - 07/2002)|
|7.||Murphy, Sabina A: 145 articles (11/2015 - 01/2002)|
|8.||Kastrati, Adnan: 144 articles (12/2015 - 01/2002)|
|9.||Jeong, Myung Ho: 139 articles (12/2015 - 03/2003)|
|10.||Waksman, Ron: 128 articles (12/2015 - 01/2002)|
|1.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
12/01/1996 - "Women who benefited the most from aspirin therapy were older, diabetic, symptomatic, or had a previous myocardial infarction. "
08/01/2004 - "A meta-analysis of randomized trials has shown a significant reduction of mortality rate in patients receiving aspirin for secondary prevention after acute myocardial infarction (AMI). "
11/01/2001 - "At the start of the eighties, in the wake of the good results obtained with aspirin in secondary prevention, two studies were launched aimed at testing the effect of aspirin on the primary prevention of myocardial infarction. "
02/15/1980 - "The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period. "
08/01/2014 - "After PCI, both groups showed a statistically significant reduction in corrected Thrombolysis In Myocardial Infarction frame count more evident in aspirin reload group (P=0.0023). "
|2.||Heparin (Liquaemin)FDA LinkGeneric
11/01/2000 - "A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction."
03/10/2009 - "Although weight-based nomograms have improved the efficacy and safety of dosing unfractionated heparin in ST-segment elevation myocardial infarction, achieving therapeutic anticoagulation in practice remains challenging. "
09/01/2001 - "The authors conclude that the use of low dose heparin appears effective and safe in cases without acute myocardial infarction. "
04/01/1990 - "SK and t-PA with or without post-thrombolytic heparin treatment appear equally effective and safe for use in routine conditions care, in all patients with acute myocardial infarction (AMI)."
11/01/1998 - "The safety and efficacy of bedside monitors of activated partial thromboplastin time (aPTT) have not been examined in a large population receiving intravenous heparin after thrombolytic treatment for acute myocardial infarction. "
|3.||clopidogrel (Plavix)FDA Link
07/04/2006 - "Clopidogrel was also associated with a significant reduction in the odds of an in-hospital death or myocardial infarction in patients who achieved partial (OR 0.30, p = 0.003) or complete STRes at 90 min (OR 0.49, p = 0.056), whereas clinical benefit was not apparent in patients who had no STRes (OR 0.98, p = 0.95) (p for interaction = 0.027). "
01/01/2006 - "After ACS with non-ST-elevation myocardial infarction the combined therapy with ASA and clopidogrel gives a better outcome than ASA alone. "
09/14/2005 - "To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events. "
05/01/2008 - "Clopidogrel (Plavix), a platelet aggregation inhibitor, has been shown to be effective in certain patients undergoing percutaneous coronary interventions, but its use in patients with acute myocardial infarction who receive a fibrinolytic strategy instead has been controversial. "
12/01/2011 - "The aim of this study was to investigate whether clopidogrel loading before arrival at the PCI centre may result in an improved outcome of primary PCI for ST-elevation myocardial infarction (STEMI). "
08/01/1981 - "The use of streptokinase (avelisine) in patients with acute myocardial infarction was accompanied by defibrinisation of the blood, by marked decrease of the aggregation facility of formed elements of the blood and its viscosity. "
04/01/2012 - "Following a series of investigations, streptokinase was discovered and demonstrated to be beneficial for the treatment of patients with acute myocardial infarction in terms of reducing short- and long-term mortality. "
01/01/2000 - "Efficacy of rapid infusion of streptokinase in patients with acute myocardial infarction."
03/01/1996 - "Thrombolytic treatment of the acute myocardial infarction with intravenous streptokinase is safe and effective, and may successfully be carried out also in district hospitals in which cardiac catheterization and cardiosurgery are inaccessible."
07/25/1994 - "patients treated with intravenous streptokinase for acute myocardial infarction reach both higher heart rates and rate-pressure products at maximum workload than their controls thus indicating that the beneficial effects of thrombolysis after acute myocardial infarction are reflected in an improved heart rate response during exercise."
|5.||glucuronyl glucosamine glycan sulfate (Vessel)IBA
06/01/2012 - "Excellent target vessel recanalization (Thrombolysis in Myocardial Infarction score of 3) and good outcome at 90 days (modified Rankin Score ≤ 2) were more common in younger patients (45% versus 14%, P = .047, and 41% versus 0%, P = .008, respectively). "
05/01/2009 - "All the treated vessels (100%) were successfully re-canalized, Trials In Myocardial Infarction (TIMI) score of 3. At 90-day follow-up, of the 5 patients treated, 2 had modified Rankin score (mRS) of < 2. This small series shows the safety and efficacy of the Penumbra System in the thrombolysis of large vessel occlusive disease."
05/01/1993 - "Different thrombolytic regimens for acute myocardial infarction proved to be equally effective in large scale mortality trials despite significant differences in their efficacy with respect to early infarct-related vessel patency as shown in smaller angiographic trials. "
12/01/2010 - "In this patient-level pooled analysis, EES compared with PES resulted in a significant and persistent reduction in target vessel failure and major adverse cardiac events at 3 years due to fewer myocardial infarction and ischemic target lesion revascularization events, which is consistent with superior safety and efficacy of the EES platform."
12/01/2009 - "The use of Endeavor versus Driver was associated with a significant reduction in target vessel revascularization through 4-year follow-up with no difference in death, nonfatal myocardial infarction, quality-adjusted survival, or total medical costs. "
07/15/2014 - "Efficacy of pre-hospital use of glycoprotein IIb/IIIa inhibitors in ST-segment elevation myocardial infarction before mechanical reperfusion in a rapid-transfer network (from the Acute Myocardial Infarction Registry of Brittany)."
12/15/2012 - "We investigated whether additional platelet inhibition with a glycoprotein IIb/IIIa inhibitor would be beneficial in reducing the risk of periprocedural myocardial infarction (PMI) in diabetic patients with high residual platelet reactivity (HPR). "
04/01/2009 - "Several clinical trials have shown that antagonists of the glycoprotein IIb/IIIa receptor decreased the incidence of death, nonfatal myocardial infarction, and the need for urgent revascularization when administered immediately before or during the 24- to 48-hour period after percutaneous coronary intervention (PCI). "
09/16/2003 - "Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary percutaneous coronary intervention for acute myocardial infarction (MI) have shown improved early clinical and angiographic outcomes with treatment. "
06/15/2013 - "Safety and efficacy of adjuvant glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention performed from the radial approach for acute ST segment elevation myocardial infarction."
|7.||Tissue Plasminogen Activator (Alteplase)FDA Link
06/01/1992 - "In this Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST), the efficacy of 3 different doses of a single rapid intravenous bolus injection of t-PA (dute-plase, Wellcome Foundation, London) in inducing coronary patency (Thrombolysis In Myocardial Infarction perfusion grade 2 or 3) in 64 patients with acute myocardial infarction presenting less than 6 hours after onset of symptoms was investigated. "
07/01/1995 - "Ideally, patients should receive alteplase as soon as possible after the onset of symptoms of acute myocardial infarction and, while therapy is most beneficial when administered early, survival is improved when the drug is administered up to 12 hours after symptom onset. "
01/01/1994 - "Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction."
12/01/1990 - "This study assesses whether administration of recombinant tissue-type plasminogen activator (rt-PA) up to 8 hours after onset of symptoms of acute myocardial infarction (AMI) may result in a significant improvement in left ventricular function. "
04/01/1990 - "Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens."
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
08/01/1996 - "Most clinical trials of angiotensin converting enzyme inhibitors after myocardial infarction have shown an improved outcome with reduction of morbidity and mortality. "
06/01/2000 - "ACE inhibitors have shown beneficial results in several studies after myocardial infarction (MI). "
03/01/2000 - "The results of major clinical trials leave us in no doubt that ACE inhibitors are useful in the treatment of patients after myocardial infarction. "
07/06/1998 - "The SAVE trial specifically evaluated the effects on post-myocardial infarction mortality and remodeling and found that ACE inhibitors were effective in reducing both. "
01/01/2008 - "Angiotensin Converting Enzyme inhibitors (ACE-I) are effective in reducing mortality and preventing left ventricular (LV) function deterioration after myocardial infarction. "
06/01/2014 - "(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38; NCT00097591)."
11/01/2013 - "Patients from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial (N = 13 608) with adjudicated ST classified per the Academic Research Consortium definitions of definite (N = 135) and probable (N = 27) were grouped into prespecified 8-hour intervals by time of onset: early (6 am-2 pm), late-day (2 pm-10 pm), and overnight (10 pm-6 am). "
04/01/2012 - "Decision model based on event occurrence in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38. "
01/31/2012 - "American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)."
08/01/2010 - "The TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) enrolled 13,608 ACS patients. "
|10.||Fibrinolytic Agents (Antithrombotic Agents)IBA
07/05/2005 - "Recent studies have indicated that a selective inhibitor of TAFIa could enhance the efficacy of existing thrombolytic agents for the treatment of acute myocardial infarction, one of the most prevalent forms of heart attacks. "
01/01/2004 - "This review examines the most significant trends in the pharmacologic therapy of ST-segment elevation myocardial infarction since the publication of these early studies: the development of fibrinolytic drugs with improved clot selectivity and improved pharmacokinetic profiles that simplify administration, making ED or even prehospital thrombolysis more practical. "
01/01/1984 - "The development of newer specific thrombolytic agents with low toxicity, without antigenicity, and available for rapid parenteral administration holds much promise for the treatment of acute myocardial infarction in the future."
10/01/2004 - "Patients in clinical trials of fibrinolytic agents have been shown to be younger, less often female, and to have lower risk characteristics and a better outcome compared with unselected patients with ST-elevation myocardial infarction. "
02/01/2013 - "Expedited treatment may influence the efficacy of nonfibrin specific thrombolytic agents in restoring early patency of the infarct-related artery (IRA), which is a major determinant of survival after ST-elevation myocardial infarction (STEMI). "
01/01/2014 - "Reperfusion by means of percutaneous coronary intervention or thrombolytic therapy is the most effective treatment for acute myocardial infarction, markedly reducing mortality and morbidity. "
12/01/2010 - "It is known that the efficacy of thrombolytic therapy in ST-segment elevation myocardial infarction (STEMI) is highly time dependent with the best efficacy when given within the so-called golden hour. "
05/25/2005 - "This article examines thrombolytic therapy, the first-line treatment for patients presenting with acute myocardial infarction in most UK hospitals. "
12/01/1994 - "Thrombolytic therapy has been proven to be highly effective and safe in patients presenting with acute myocardial infarction. "
05/01/1996 - "Multiple clinical trials have proven that thrombolytic therapy is an effective treatment for acute myocardial infarction. "
|2.||Angioplasty (Angioplasty, Transluminal)
09/01/2008 - "Primary angioplasty is the most effective treatment of ST-segment elevation acute myocardial infarction (STEMI). "
11/01/2005 - "Primary angioplasty is the best treatment of acute myocardial infarction but fails to achieve adequate myocardial reperfusion in 25% to 30% of patients, despite TIMI grade 3 flow. "
09/01/2004 - "The most important observation was that elderly patients with myocardial infarction may be safely and effectively treated with primary coronary angioplasty. "
12/01/2001 - "Direct coronary angioplasty (PTCA) represents the most effective treatment for acute myocardial infarction. "
05/01/2001 - "A mechanical approach to reperfusion using direct coronary angioplasty is now an established and effective treatment for acute myocardial infarction, but it is not immediately available at most community hospitals. "
08/01/2002 - "Since 1995, when the very good results of the stent implantation in patients with acute myocardial infarction were published, there has been a general trend to more stenting also in the Czech Republic. "
01/01/2010 - "Patients with a history of (V)LST had a significantly greater stent burden and a higher number of previous myocardial infarctions than the control patients.There"
04/01/2006 - "The cause of the arrest was acute myocardial infarction which was treated successfully with percutaneous cardiac intervention (PCI) and a stent placement. "
02/01/2011 - "In conclusion, IVUS guidance for bare metal stent implantation improved the acute procedural results (angiographic minimum lumen diameter) and thereby reduced angiographic restenosis and repeat revascularization and major adverse cardiac events, with a neutral effect on death and myocardial infarction during a follow-up period of 6 months to 2.5 years."
11/01/2009 - "Over the last 20 years, the outcome of ACS and PCI patients has considerably improved, thanks to better pharmacologic environment, urgent reperfusion in STEMI (ST elevation myocardial infarction), timely revascularisation in non-ST elevation ACS (NSTEACS) and improved PCI techniques, particularly widespread use of stents. "
|4.||Transplantation (Transplant Recipients)
09/14/2012 - "In summary, this is the first study to successfully differentiate piPSCs-ECs from piPSCs and demonstrate that transplantation of piPSC-ECs improved cardiac function after myocardial infarction via paracrine activation. "
10/15/2012 - "The transplantation of (PC)MSC in an acute model of myocardial infarction showed a significantly improved survival of transplanted (PC)MSC with concomitantly enhanced miR-107 expression in (PC)MSC-transplanted animal hearts. "
01/01/2011 - "In Sprague-Dawley (SD) rats with left anterior descending artery (LAD)-induced myocardial infarction (MI), the ADAS-GFs transplanted group had the left ventricular function significantly improved compared with the ADAS transplanted group or the control group at 12 weeks post transplantation. "
12/01/2009 - "Engraftments of SKMs with knockdowned miRNA-181a similarly improved cardiac function as SKM transplantation but significantly decreased the arrhythmogenic effect of SKM transplantation in rats with experimental myocardial infarction."
02/01/2007 - "Transplantation of AM gene-engineered MSCs improved cardiac function after myocardial infarction significantly more than MSCs alone. "
|5.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/01/2015 - "Many studies have unequivocally demonstrated that coronary artery bypass grafting surgery generally leads to significant reduction in heart rate variability, which is even more pronounced than after myocardial infarction. "
09/10/2013 - "The prevalence of myocardial infarction history, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) history in male group were significantly greater than that in female group (48.0% vs 39.9%, P < 0.05; 30.6% vs 22.3%, P < 0.05; 19.9% vs 10.3%, P < 0.01). "
04/01/2006 - "In patients with previous myocardial infarction, treatment with skeletal myoblasts in conjunction with coronary artery bypass is safe and feasible and is associated with an increased global and regional left ventricular function, improvement in viability, and perfusion of cardiac tissue and no significant incidence of arrhythmias."
03/01/2004 - "HRQoL improved significantly in patients after coronary artery bypass grafting (CABG) but not in patients after myocardial infarction. "
07/01/2013 - "Major recent studies such as SYNTAX and FREEDOM have confirmed that coronary artery bypass grafting (CABG) remains the gold standard treatment in terms of survival and freedom from myocardial infarction and the need for repeat revascularization. "